KREBSBIO61.00

Krebs Biochemicals and Industries Limited

· Pharma & Health
₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹132 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation6.86.76.4
+ Finance Costs4.75.97.1
+ Other Non-cash Items0.00.00.2
+ Other — Cash Effects are Investing / Financing0.0-0.10.0
Changes in Working Capital
+ Inventories2.13.80.3
+ Trade Receivables — Current-1.41.90.2
+ Other Financial Assets — Current-0.2-0.30.1
+ Other Financial Assets — Non-current-2.72.8-0.0
+ Other Current Assets0.6-1.20.2
+ Other Non-current Assets-1.1-0.9-0.5
+ Trade Payables — Current3.7-0.8-2.9
+ Other Financial Liabilities — Current3.74.24.2
+ Other Current Liabilities5.6-2.4-0.5
+ Other Non-current Liabilities-0.1-0.3-0.1
+ Provisions — Current-0.10.00.0
+ Provisions — Non-current0.4-0.10.1
Cash from Operating Activities
Profit Before Tax (per I/S)-19.7-26.9-16.9-14.1
+ Total Adjustments (incl. Working Capital)22.019.015.0
Cash from Operations (pre-tax)2.3-7.9-1.9
+ Income Taxes Paid0.00.00.0
Cash from Operating Activities2.3-7.9-1.9
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)7.85.14.0
+ Disp of Fixed Assets0.00.20.4
Cash from Investing Activities-7.8-5.0-3.6
Cash from Financing Activities
+ Proceeds from Borrowings10.341.010.3
+ Repayment of Borrowings0.022.3-2.3
+ Interest Paid4.75.97.1
Cash from Financing Activities5.612.95.5
Net Changes in Cash (pre-FX)0.10.0-0.0
Net Changes in Cash0.10.0-0.0
Closing Cash0.1
Reference Items
EBITDA-8.7-15.0-5.5-2.5
EBITDA Margin %-17.30-34.70-22.97-10.05
Free Cash Flow (CFO − Capex)-5.5-13.0-5.9-5.9
Free Cash Flow to Equity-0.2-0.4
Free Cash Flow per Basic Share-2.56-6.04-2.75-2.75
Cash Flow to Net Income-0.120.290.11
Cash Paid for Taxes0.00.00.0
Cash Paid for Interest4.75.97.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.